The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options ...

CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a year after it stopped covering it in favor of Novo Nordisk’s Wegovy.

CVS Caremark, one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered medications last year, drugmaker Eli Lilly said.

CVS Caremark laid out its renewed pledge to American businesses, unions and health plans—building on what the company said it is doing to deliver greater transparency, lower drug costs and better ...

CVS Health does a 180. On May 28, CVS Caremark, the pharmacy benefits manager (PBM) under CVS Health's umbrella, announced it ...

CVS Caremark, one of the nation's largest pharmacy benefit managers, recently announced a new partnership with the discount drug service GoodRx, aiming to lower out-of-pocket prescription costs for ...

In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a win for GLP-1 patients.

When the Federal Trade Commission started to investigate pharmacy benefit managers in 2022, the agency asked the country’s largest PBMs to provide employee data, including names, responsibilities, and ...

DALLAS and NEW YORK, July 14, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in ...

A U.S. federal judge has ordered CVS Caremark, the pharmacy benefits arm of CVS Health, to pay $95 million over allegations it overbilled Medicare for prescription drugs. The decision was made by ...

Rising prescription drug costs remain a top healthcare concern, with pharmacy benefit managers (PBMs) facing heightened scrutiny for their role in managing prescription drug benefits for insurers and ...